Tag: RET fusion-positive tumors

Home / RET fusion-positive tumors

Categories

Selpercatinib is approved by FDA for locally advanced or metastatic RET fusion-positive solid tumors

November 2022: Selpercatinib (Retevmo, Eli Lilly and Company) received accelerated approval from the Food and Drug Administration to treat adult patients with RET-fused solid tumours that are locally ...
ret-fusion-positive-tumors

Scan the code